LaBarre Michael J.'s Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Apr 19, 2023
- Accession no.
- 0001415889-23-006740
- Filed
- Apr 19, 2023
- Trade date
- Apr 18, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $360.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBarre Michael J.CIK 0001507174 | Officer (SVP, CHIEF TECHNICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 18, 2023 | Common Stock | MOption exerciseAcquired | +10,000 | $18.41 | +$184,100 | 151,911 | Direct | |
| Apr 18, 2023 | Common Stock | SSaleDisposed | −10,000 | $36.00 | −$360,000 | 141,911 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 18, 2023 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 27,505 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.